AI assistant
KALA BIO, Inc. — Director's Dealing 2021
Jan 5, 2021
35091_dirs_2021-01-05_96757cbf-bc3a-4699-9aea-9d7b64f2e000.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2021-01-04
Reporting Person: Reumuth Mary (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-04 | Common Stock | A | 22666 | — | Acquired | 147959 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-04 | Stock Option (right to buy) | $6.86 | A | 90667 | Acquired | 2031-01-03 | Common Stock (90667) | Direct |
Footnotes
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2022, as to 1/3 of the shares underlying the RSUs on January 4, 2023 and as to the final 1/3 of shares underlying the RSUs on January 4, 2024.
F2: Includes 99,666 unvested RSUs.
F3: This option was granted on January 4, 2021 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.